Keyphrases
Bone Resorption
20%
Glucagon
47%
Glucagon Secretion
16%
Glucagon-like
59%
Glucose-dependent Insulinotropic Polypeptide
100%
Hemodynamic Effects
16%
Hemoglobin A1c (HbA1c)
20%
Insulin
18%
Intravenous Glucose
15%
Medication Review
22%
Meta-analysis
17%
Placebo
23%
Poison Control Centers
18%
Receptor Antagonist
18%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
16%
Systematic Meta-analysis
24%
Type 2 Diabetes Mellitus (T2DM)
16%
Type 2 Diabetic Patients
49%
Pharmacology, Toxicology and Pharmaceutical Science
Gastric Inhibitory Polypeptide
64%
Gastric Inhibitory Polypeptide Receptor
17%
Glucagon-Like Peptide-1
36%
Lipid Emulsion
16%
Non Insulin Dependent Diabetes Mellitus
36%
Obesity
16%
Placebo
33%
Poison Control Center
24%
Receptor Antagonist
18%
Toxic Injury
26%
Medicine and Dentistry
Gastric Inhibitory Polypeptide
56%
Glucagon Like Peptide 1
24%
Meta-Analysis
17%
Patient with Type 2 Diabetes
26%
Placebo
20%
Receptor Antagonist
16%
Systematic Review
17%
